Application of a compact trickle-bed bioreactor for the removal of odor and volatile organic compounds emitted from a wastewater treatment plant.

A compact trickle-bed bioreactor (CTBB) was tested for the removal of volatile organic compounds (VOCs) and hydrogen sulphide (H2S) present in the exhaust air of a wastewater treatment plant. At gas-flow rates varying between 2.0 and 30.0 m3/h and for specific pollutant loads up to 20 g/(m3·h), removal efficiencies for H2S and VOC were >95%. The CTBB was designed for a maximum H2S concentration of ∼200 ppm and removal efficiencies >97% were noticed. VOC concentrations were in the range of 25-240 ppmv and the removal efficiency was in the range of 85-99%. Possible consequences of an excessive pollutant overload and the time required for regenerating the microbial activity and reviving stable process conditions in the CTBB were also investigated. An increase in the H2S concentration from 400 to 600 ppmv for a few hours caused bioreactor poisoning; however, when original H2S concentrations were restored, stable CTBB operation was ascertained within 3 h.

Odor and volatile organic compounds biotreatment using compact trickle bed bioreactors (CTBB) in a wastewater treatment plant.

The main aim of this study was to optimize and maximize the impacts of odor and volatile organic compounds (VOCs) biodegradation in a wastewater treatment plant utilizing a pilot-scale compact trickle bed bioreactor (CTBB). A CTBB was built and tested for its long-term performance during which gases were supplied from the tank containing semi-liquid fats, oils, and fat waste. The concentrations of pollutants ranged from 0 to 140.75 mg/m3 H2S, 0 to 2500 mg/m3 VOCs, and 0 to 21.5 mg/m3 NH3. The CTBB was tested at different gas flow rates and at two pH values for the liquid phase: pH = 7.0 and 5.0. In the liquid phase, the pollutant removal efficiency was higher at pH = 7.0 than at pH = 5.0. Overall, the removal efficiency was between 81.5 % and 99.5 % for the VOCs and 87.5 % and 98.9 % for H2S, while NH3 removals were >99 %.

A preface to the special issue of optimization and engineering dedicated to SDEWES 2020 conferences.

Global warming and climate change call for urgent minimization of the impact of human activities on the environment. There is a great need for the improvement of resource efficiencies by integrating various life-supporting systems. The challenge is on the energy, water and environment systems to integrate and become more sustainable. This research field has received increased attention over the past years with studies across the energy, water and environment systems that optimized different engineering problems. The present Special Issue stems from four Conferences on Sustainable Development of Energy, Water and Environment Systems held in 2020, in four countries of three continents. This review introduction article intends to introduce the topical field and the articles included in this Special Issue of Optimization and Engineering.

Continuous glucose monitoring as a screening tool for neonatal hypoglycemia in infants of diabetic mothers.

Objective: To assess the plausibility of using the continuous glucose monitoring as a sole source of data for the screening of the neonatal hypoglycemia.Study design: Infants of mothers with diabetes were screened for neonatal hypoglycemia (less than 2.5 mmol/l after 4 h of life). Initial measurement was performed using point of care analyzer. We applied continuous glucose monitoring system subsequently. Infants were monitored up to 5 days or until discharge.Results: Out of 32 infants 11 had postnatal hypoglycemia resolved within 12 h of life. Two infants had hypoglycemia found due to continuous glucose monitoring after 24 h of life when sufficient feeding was established and they did not show any signs of hypoglycemia. We did not have any false negative measurements. No infant showed clinical signs of neonatal hypoglycemia.Conclusions: Continuous glucose monitoring is plausible and safe to use for screening of neonatal hypoglycemia. It operates well within the range that is accepted as safe for neurodevelopment. In addition, it can be used after first day of life where regular screening ends. Limitation of this method is possible alarm negligence of caregivers.

Sexual Dysfunction in Women Treated for Type 1 Diabetes and the Impact of Coexisting Thyroid Disease.

INTRODUCTION: More sexual problems are reported among people treated for diabetes; however, this situation is less explored in women than in men. AIM: To analyze the presence and causal links of female sexual dysfunction (FSD) among Czech women treated for type 1 diabetes. METHODS: 40 women completed a national version of the Female Sexual Function Index (FSFI), Female Sexual Distress Scale-revised (FSDS-R), and Beck's Depression Inventory-II (BDI-II). A metabolic and endocrine analysis was done using blood samples. Data were statistically analyzed using SPSS v.24 and the R environment. MAIN OUTCOME MEASURES: Patient details (personal information, diabetes-related data, and sex history), sexual performance (the FSFI and FSDS-R scores), and level of depression (the BDI-II score) were measured. RESULTS: FSD was present in 58% of the participants (based on the FSFI score), and 38% women declared significant sexual distress (according to their FSDS-R score). Even though only 4 women fulfilled the criteria for depression, we observed a strong association between BDI-II and FSFI (for total FSFI score P = .012, ρ = -0.394) resp. FSDS-R scores (P < .001, ρ = 0.552). Although we were not able to establish a clear direct connection between FSD and metabolic control, BDI-II scores were closely correlated with glycosylated hemoglobin (P = .009, ρ = 0.407). The duration of diabetes (based on FSDS-R: P = .046) but neither age nor the presence of chronic diabetic microvascular complications was associated with a higher FSD occurrence. We also observed an association between FSD and the presence of autoimmune hypothyroidism, even when successfully treated (FSDS-R: P = .009; FSFI: P = .067). CONCLUSION: FSD is more common in women with type 1 diabetes than in healthy women, and coexisting thyroid autoimmune disease seems to exacerbate FSD. Women suffering from type 1 diabetes, and particularly those with additional endocrinopathies, should be actively screened for FSD. Stechova K, Mastikova L, Urbaniec K, et al. Sexual Dysfunction in Women Treated for Type 1 Diabetes and the Impact of Coexisting Thyroid Disease. Sex Med 2019;7:217-226.

Lessons Learned from Implementing a New Testing/Educational Tool for Patients Using an Insulin Pump.

BACKGROUND: To improve insulin pump therapy results, a special test for patients was devised. The model successfully used to achieve a license to operate different machines was followed. METHODS: The test (a practice and a full run, with a time limit) contained 42 questions, each with four optional choices, and could be answered online. Patients could familiarize themselves with the whole question pool first. Patients could repeat a full run attempt if they failed and were offered focused remedial education. The study group composed of adults, 46 females, and 54 males, all treated for type 1 diabetes, 38/100 newly introduced to insulin pump therapy. RESULTS: Eighty-five of 100 patients successfully completed their first full run attempt (80% or higher correct answers) and 3 of 100 on their second full run attempt; 12 of 100 patients were not able to succeed. The median of the test score was 2 mistakes (range 0-17 mistakes). The most problematic topics were diet and insulin regimens and their application. The crucial factor influencing the test score was the willingness to try practice run(s). Those who practiced had a significantly higher total test score with better results in 5 of 8 tested knowledge domains. Age and diabetes existing >15 years had an impact on the result, too. Both patients' and caregivers' opinions on the test were predominantly positive (or neutral). CONCLUSIONS: The type of test introduced is a good tool for checking a patient's theoretical knowledge and indirectly revealing a patient's level of motivation.